Trials / Terminated
TerminatedNCT01042678
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MP0112 | Single intravitreal injection of MP0112 in the study eye |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2010-01-05
- Last updated
- 2014-05-13
- Results posted
- 2014-05-13
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01042678. Inclusion in this directory is not an endorsement.